Clinical trials: Borderline Personality Disorder (BPD)
Borderline Personality Disorder
PET Imaging and Olanzapine Treatment in Borderline Personality Disorder
The overall design of the study is to perform both a PET and MRI scan on objectively identified borderline personality disorder patients, to treat them with olanzapine for 8 weeks, and to then re-scan the patients with PET.
- Trial name
- NCT00275301
- Testing
- olanzapine
- Where
- United States
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Borderline Personality Disorder
Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD)
This study evaluates the safety and tolerability of brexpiprazole in the treatment of adults with borderline personality disorder.
- Trial name
- NCT04186403
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Borderline Personality Disorder, Self-Injurious Behavior
N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD
Self-Injurious Behavior (SIB) is a dangerous and common symptom in Borderline Personality Disorder (BPD) patients. Approximately 70% of patients with BPD engage in SIB at some point, compared to 17.5% of patients with other…
- Trial name
- NCT00539188
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Borderline Personality Disorder
Cognitive Reappraisal Training for Borderline Personality
Previous work by the study group convinced the study team to pursue development of focused cognitive reappraisal training as a novel approach to treatment of BPD, either as stand-alone treatment or in concert with evidence-based…
- Trial name
- BPD (NCT04967222)
- Testing
- Cognitive Reappraisal by Distancing, Control Downregulate Condition
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Borderline Personality Disorder
Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD)
The Primary objective of this study is to evaluate Seroquel XR in the treatment of borderline personality disorder (BPD). As in many initial randomized control trials, the study will be of relatively short duration - 8 weeks - to…
- Trial name
- NCT00880919
- Testing
- quetiapine extended-release
- Where
- 3 sites in United States
- Volunteers
- 95 people
- Sponsor
- University of Minnesota
Borderline Personality Disorder
Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population
PORTICO is a Phase IIb study to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population.
- Trial name
- NCT04932291
- Testing
- vafidemstat
- Where
- 21 sites in United States, Bulgaria and 3 more
- Volunteers
- 211 people
- Sponsor
- Oryzon Genomics S.A.
Borderline Personality Disorder (BPD)
Researching the Effectiveness of a Alivis, a Digital Health Application for Borderline Personality Disorder
This randomized controlled trial (RCT) with 470 patients diagnosed with Borderline Personality Disorder (BPD) aims to investigate the effectiveness of the unguided digital therapeutic alivis for patients with BPD as defined in…
- Trial name
- REVALDI-BPD (NCT06601907)
- Testing
- alivis
- Where
- Germany
- Volunteers
- 286 people
- Sponsor
- Gaia AG
Borderline Personality Disorder
Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD)
Participants will be randomized to either Mifepristone 600mg once daily for seven days or Placebo tablet once daily for seven days. Rating scales, vital signs, cortisol levels will be collected for evaluation.
- Trial name
- NCT01212588
- Testing
- mifepristone
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Indiana University